NEWS | Innovation for Life
Prestige Biopharma Signs Technology Transfer Agreement with Human Vaccine & Enso for Sputnik Light COVID-19 vaccine
SINGAPORE, November 8, 2021 – Prestige Biopharma Limited, a Singapore-based biopharmaceutical with global presence, announced that the company signed a technology transfer agreement with Human Vaccine LLC (HV), a wholly owned subsidiary of the Russian Direct Investment Fund (RDIF) and ENSO Healthcare DMCC(ENSO) on November 5, 2021 for the production of ‘Sputnik Light’ COVID-19 vaccine.
The single-component Sputnik Light vaccine that PBP will be producing, after the technical transfer, is designed as a single-dose vaccine consisting of the first dose of Sputnik V vaccine, using one type of vector (Ad26 adenovirus). Sputnik Light is currently being approved for use in the growing number of countries where Sputnik V has been approved.
HV holds a license for undertaking the manufacture and sale of Sputnik vaccine and ENSO is RDIF’s coordination partner for sourcing and distribution of Sputnik vaccine. In order to respond to the growing demands of Sputnik Light, HV and ENSO have entered into this technical transfer agreement with Prestige Biopharma for manufacturing of Sputnik Light. The technical transfer agreement includes DS (Drug Substance) and DP (Drug Product) production technology transfer and validation.
Prestige Biopharma Group recently completed its Osong Campus 1 Annex in South Korea and its commercial vaccine production unit has been installed in the building. Prestige Biopharma’s global-scale Vaccine Center, being built with its affiliate, Prestige Biologics’ proprietary technology ALITA Smart BioFactoryTM in Osong Campus 2, will be equipped with a total of 104,000 litres of production capacity, and this capacity will be allocated to the HV-ENSO contract and Huons Global Consortium.
Prestige Biopharma is actively establishing a drug product (DP) production capacity (filling and packaging) for a smooth global vaccine supply. Such efforts include recent purchase of a state-of-the-art aseptic filling machine from Cytiva for DP manufacturing.
Dr. Lisa S. Park, CEO of Prestige Biopharma, commented: “Prestige Biopharma international scale Vaccine Centre is designed to enable mass-production of various vaccines in short period of time. Our first project with Huons Global Consortium is showing visible progress and results. Through this technical transfer agreement with HV and ENSO, we will also be preparing to produce Sputnik Light vaccine and the company feels a tremendous responsibility” and “we will keep contributing to the growing global demands for COVID-19 vaccine production with the company’s unmatched production facility and technologies.”